Various metals of unknown function in the body (Cd, Cr, Hg, Pb, U), trace elements in excessive concentrations (Co, Cu, Fe, Zn), or metals used in cancer therapy (Pt, V), accumulate in the mammalian kidney, largely in the proximal tubule (PT) cells, and cause functional and structural damage that results in reabsorptive and secretory defects. The intracellular mechanisms of their toxicity in the PT cells are not well known. Recent studies have indicated an oxidative stress with associated lipid peroxidation, apoptosis, and necrosis as common phenomena in the course of nephrotoxicity of these metals. However, a number of other phenomena, such as the selective inhibition and/or loss of various membrane transporters, enhancement of ion conductances, increased cytoplasmic concentration of calcium, deranged cytoskeleton and cell polarity, impaired endocytosis, swelling and fragmentation of mitochondria, increased expression of metallothionein, heat-shock and multidrug resistance proteins, loss of cell membrane integrity, as well as the damage of mitochondrial and genomic DNAs have been fragmentarily demonstrated for the action of some toxic metals, but their importance for the course of nephrotoxicity and the sequence of events in relation to oxidative stress, apoptosis, and necrosis have not been clearly established. Recent studies of metal toxicity in various tissues and cells of non-renal and renal origin enable us to estimate ‘causes and consequences’ of various phenomena in the metal-induced nephrotoxicity, and to assemble them in a possible common, time-related sequence.

1.
Bergeron M, Goodyear PR, Gougoux A, Lapointe JY: Pathophysiology of renal hyperaminoacidurias and glucosuria; in Seldin DW, Giebisch G (eds): The Kidney, Physiology and Pathophysiology, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2000, vol 2, pp 2211–2233.
2.
Dock L, Vahter M: Metal toxicology; in Ballantyne B, Marrs T, Syversen T (eds): General and Applied Toxicology, ed 2. London, Macmillan Reference Ltd, 1999, vol 3, pp 2049–2078.
3.
Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460–464.
4.
Evangelou AM: Vanadium in cancer treatment. Crit Rev Oncol Hematol 2002;42:249–265.
5.
Domingo JL: Vanadium and tungsten derivatives as antidiabetic agents – a review of their toxic effects. Biol Trace Element Res 2002;88:97–112.
6.
Sabolic I, Ljubojevic M, Herak-Kramberger CM, Brown D: Cd-MT causes endocytosis of brush-border transporters in rat renal proximal tubules. Am J Physiol Renal Physiol 2002;283:F1389–F1402.
7.
Sabolic I, Herak-Kramberger CM, Antolovic R, Breton S, Brown D: Loss of basolateral invaginations in proximal tubules of cadmium-intoxicated rats is independent of microtubules and clathrin. Toxicology 2006;218:149–163.
8.
Zalups RK, Ahmad S: Molecular handling of cadmium in transporting epithelia. Toxicol Appl Pharmacol 2003;186:163–188.
9.
Thevenod F: Nephrotoxicity and the proximal tubule. Nephron Physiol 2003;93:87–93.
10.
Abouhamed M, Gburek J, Liu W, Torchalski B, Wilhelm A, Wolff NA, Christensen EI, Thevenod F, Smith CP: Divalent metal transporter 1 in the kidney proximal tubule is expressed in late endosomes/lysosomal membranes: implications for renal handling of protein-metal complexes. Am J Physiol Renal Physiol 2006;290:F1525–F1533.
11.
Zalups RK: Molecular interactions with mercury in the kidney. Pharmacol Rev 2000;52:113–143.
12.
Ludvig T, Reithmuller C, Gekle M, Schwerdt G, Oberleithner H: Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004;66:196–202.
13.
Bridges CC, Zalups RK: Molecular and ionic mimicry and the transport of toxic metals. Toxicol Appl Pharmacol 2005;204:274–308.
14.
Dalton TP, He L, Wang B, Miller ML, Jin L, Stringer KF, Chang X, Baxter CS, Nebert DW: Identification of mouse SLC39A8 as the transporter responsible for cadmium-induced toxicity in the testis. Proc Natl Acad Sci USA 2005;102:3401–3406.
15.
Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH: Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1–10.
16.
Herak-Kramberger CM, Sabolic I: The integrity of renal cortical brush-border and basolateral membrane vesicles is damaged in vitro by nephrotoxic heavy metals. Toxicology 2001;156:139–147.
17.
Bergendi L, Benes L, Durackova Z, Ferencik M: Chemistry, physiology and pathology of free radicals. Life Sci 1999;65:1865–1874.
18.
Kourie JI: Interaction of reactive oxygen species with ion transport mechanisms. Am J Physiol Cell Physiol 1998;275:C1–C24.
19.
Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol 2003;552:335–344.
20.
Suzuki YJ, Forman HJ, Sevanian A: Oxidants as stimulators of signal transduction. Free Radic Biol Med 1997;22:269–285.
21.
Koizumi T, Li ZG: Role of oxidative stress in single dose, cadmium-induced testicular cancer. J Toxicol Environ Health 1992;37:25–36.
22.
Casalino E, Sblano C, Landriscina C: Enzyme activity alteration by cadmium administration to rats: the possibility of iron involvement in lipid peroxidation. Arch Biochem Biophys 1997;346:171–179.
23.
Yiin SJ, Chern CL, Sheu JY, Tseng WC, Lin TH: Cadmium-induced renal lipid peroxidation in rats and protection by selenium. J Toxicol Environ Health A 1999;57:403–413.
24.
Pourahmad J, O’Brien PJ, Jokar F, Daraei B: Carcinogenic metal induced sites of reactive oxygen species formation in hepatocytes. Toxicol In Vitro 2003;17:803–810.
25.
Boobis AR, Fawthrop DJ, Davies DS: Mechanisms of cell death. Trends Pharmacol Sci 1989;10:275–280.
26.
Zhang JG, Lindup WE: Cisplatin-induced nephrotoxicity in vitro – increases in cytosolic calcium concentration and the inhibition of cytosolic and mitochondrial protein kinase C. Toxicol Lett 1996;89:11–17.
27.
Tang W, Shaikh ZA: Renal cortical mitochondrial dysfunction upon cadmium metallothionein administration to Sprague-Dawley rats. J Toxicol Environ Health A 2001;63:221–235.
28.
Wang Y, Fang J, Leonard SS, Rao KMK: Cadmium inhibits the electron transfer chain and induces reactive oxygen species. Free Radic Biol Med 2004;36:1434–1443.
29.
Lee WK, Bork, U, Gholamrezaei F, Thevenod F: Cd2+-induced cytochrome c release in apoptotic proximal tubule cells: role of mitochondrial permeability transition pore and Ca2+ uniporter. Am J Physiol Renal Physiol 2005;288:F27–F39.
30.
Susin SA, Zamzami N, Kroemer G: Mitochondria as regulators of apoptosis: Doubt no more. Biochim Biophys Acta 1998;1366:151–165.
31.
Padanilam BJ: Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am J Physiol Renal Physiol 2003;284:F608–F627.
32.
Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS: Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004;287:C817–C833.
33.
Lenaz G: Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta 1998;1366:53–67.
34.
Kowaltowski AJ, Vercesi AE: Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999;26:463–471.
35.
Orrenius S, McConkey DJ, Bellomo G, Nicotera P: Role of Ca2+ in toxic cell killing. Trends Pharmacol Sci 1989;10:281–285.
36.
Ermak G, Davies KJA: Calcium and oxidative stress: from cell signalling to cell death. Mol Immunol 2001;38:713–721.
37.
Hajnoczki G, Davies E, Madesh M: Calcium signalling and apoptosis. Biochem Biophys Res Commun 2003;304:445–454.
38.
Smith JB, Dwyer SD, Smith L: Cadmium evokes inositol polyphosphate formation and calcium mobilization. J Biol Chem 1989;264:7115–7118.
39.
Yeh JH, Chung HM, Ho CM, Jan CR: Mercury-induced Ca2+ increase and cytotoxicity in renal tubular cells. Life Sci 2004;74:2075–2083.
40.
Jewell SA, Bellomo G, Thor H, Orrenius S, Smith M: Bleb formation in hepatocytes during drug metabolism is caused by disturbances in thiol and calcium ion homeostasis. Science 1982;217:1257–1259.
41.
Zuvic-Butorac M, Herak-Kramberger CM, Krilov D, Sabolic I, Herak JN: EPR study of lipid phase in renal cortical membrane organelles from intact and cadmium-intoxicated rats. Biochim Biophys Acta 2005;1718:44–52.
42.
Szalai G, Krishnamurthy R, Hajnoczky G: Apoptosis-driven by IP3-linked mitochondrial calcium signals. EMBO J 1999;18:6349–6361.
43.
Duchen MR: Mitochondria and calcium: from cell signalling to cell death. J Physiol 2000;529:57–68.
44.
Calamita G, Ferri D, Gena P, Liquori GE, Cavalier A, Thomas D, Svelto M: The inner mitochondrial membrane has aquaporin-8 water channels and is highly permeable to water. J Biol Chem 2005;280:17149–17153.
45.
Perry DK, Smyth MJ, Stennicke HR, Salvesen GS, Duriez P, Poirier GG, Hannun YA: Zinc is a potent inhibitor of the apoptotic protease, caspase 3. J Biol Chem 1997;272:18530–18533.
46.
Shiraishi Y, Nagai J, Murakami T, Takano M: Effect of cisplatin on H+ transport by H+-ATPase and Na+/H+ exchanger in rat renal brush-border membrane. Life Sci 2000;67:1047–1058.
47.
Kim JS, He L, Lemaster JL: Mitochondrial permeability transition: common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003;304:463–470.
48.
Andrews GK: Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 2000;59:95–104.
49.
Shaikh ZA, Vu TT, Zaman K: Oxidative stress as a mechanism of chronic cadmium-induced hepatotoxicity and renal toxicity and protection by antioxidants. Toxicol Appl Pharmacol 1999;154:256–263.
50.
Agarwal A, Balla J, Alam J, Croatt AJ, Nath KA: Induction of heme oxygenase in toxic renal injury – a protective role in cisplatin nephrotoxicity in the rat. Kidney Int 1995;48:1298–1307.
51.
Weinberg JM: The cell biology of ischemic renal injury. Kidney Int 1991;39:476–500.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.